1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Analysis & Statistics in Oceania Countries, June 2014 (p6)

Pharmaceutical Analysis & Statistics in Oceania Countries, June 2014 (p6)

151-180 of about 200 reports

Purchase Reports From Reputable Market Research Publishers

Sigma Pharmaceuticals Ltd in Retailing (Australia)

Sigma Pharmaceuticals Ltd in Retailing (Australia)

  • $ 143
  • Company report
  • June 2014
  • by Euromonitor International

After a successful redefinition of its business strategy, Sigma Pharmaceuticals has been focusing on strengthening its pharmacy-based retail business. In the first quarter of 2013, Sigma Pharmaceuticals ...

  • Industries : Pharmaceutical
  • Countries : Australia
Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Drug and Medication
  • Countries : World, Australia
Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology, Drug and Medication
  • Countries : World, Australia, Japan
Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Drug and Medication, Pathology
  • Countries : World, Australia, Japan
Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market ...

  • Industries : Drug and Medication
  • Countries : Australia
ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Drug and Medication, Pathology
  • Countries : World, Australia
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : World, Australia
Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Drug and Medication
  • Countries : World, Australia
Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World
New Zealand Pharmaceuticals Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

New Zealand Pharmaceuticals Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

Summary New Zealand Pharmaceuticals Ltd. (NZ Pharma) is a biotechnology service provider. The company extracts and purifies biochemicals from by-products of the New Zealand meat processing industry. Its ...

  • Industries : Pharmaceutical
  • Countries : New Zealand
Phosphagenics Limited : Ingredients - Company Profile, SWOT and Financial Report

Phosphagenics Limited : Ingredients - Company Profile, SWOT and Financial Report

  • $ 125
  • Company report
  • May 2014
  • by Canadean Ltd

Synopsis Canadean's "Phosphagenics Limited : Ingredients - Company Profile, SWOT & Financial Report" contains in depth information and data about the company and its operations. The profile contains a ...

  • Countries : Australia, Japan
New Zealand Pharmaceuticals and Healthcare Report Q3 2014

New Zealand Pharmaceuticals and Healthcare Report Q3 2014

  • $ 1 300
  • Industry report
  • May 2014
  • by Business Monitor International

Includes 3 FREE quarterly updates BMI View: The attractiveness of New Zealand's pharmaceutical market remains highly dependent on the decisions made by the Pharmaceutical Management Agency (PHARMAC). ...

  • Industries : Pharmaceutical, Healthcare
  • Countries : New Zealand
Swisse Vitamins Pty Ltd in Consumer Health (Australia)

Swisse Vitamins Pty Ltd in Consumer Health (Australia)

  • $ 143
  • Company report
  • April 2014
  • by Euromonitor International

Swisse Vitamins Pty Ltd looks to continue its rapid expansion through focusing on international markets and continuing its strategy of engaging high profile brand ambassadors. Swisse has already ventured ...

  • Industries : Vitamin and Supplement, Vitamin and Supplement
  • Countries : Australia
Pharmaceuticals in New Zealand

Pharmaceuticals in New Zealand

  • $ 350
  • Industry report
  • April 2014
  • by MarketLine

Introduction Pharmaceuticals in New Zealand industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2009-13, and forecast to 2018). ...

  • Industries : Pharmaceutical, Pathology, Drug and Medication
  • Countries : New Zealand
Ego Pharmaceuticals Pty Ltd in Consumer Health (Australia)

Ego Pharmaceuticals Pty Ltd in Consumer Health (Australia)

  • $ 143
  • Company report
  • April 2014
  • by Euromonitor International

Ego Pharmaceuticals will continue to reinforce its dominant position in Australia while focusing on expansion within the Asia-Pacific region, the Middle East and the UK to drive additional value growth. ...

  • Industries : Pharmaceutical
  • Countries : Australia
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

  • $ 4 995
  • Industry report
  • March 2014
  • by GBI Research

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability Summary GBI Research, the leading business intelligence ...

  • Industries : Drug and Medication, Pharmaceutical, Pathology
  • Countries : Asia, India, China, Japan, Australia
Vitamin and Supplement Manufacturing in Australia - Industry Market Research Report

Vitamin and Supplement Manufacturing in Australia - Industry Market Research Report

  • $ 965
  • Industry report
  • February 2014
  • by Ibisworld

Healthy and functional: Health awareness and product innovation are driving industry growth Vitamin and Supplement Manufacturing in Australia Vitamin and supplement manufacturers primarily develop and ...

  • Industries : Vitamin and Supplement, Vitamin and Supplement
  • Countries : Australia
Orphan Australia Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Orphan Australia Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

Summary Orphan Australia Pty Ltd (Orphan Australia) is a pharmaceutical company. The company provides novel therapies for the treatment of serious or life-threatening diseases in Australia and New Zealand. ...

  • Industries : Pharmaceutical
  • Countries : Australia
Pharmaceuticals in Australia: ISIC 2423

Pharmaceuticals in Australia: ISIC 2423

  • $ 657
  • Industry report
  • January 2014
  • by Euromonitor International

Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at ...

  • Industries : Pharmaceutical
  • Countries : Australia
Psychiatric Hospitals in Australia - Industry Market Research Report

Psychiatric Hospitals in Australia - Industry Market Research Report

  • $ 965
  • Industry report
  • December 2013
  • by Ibisworld

Stable condition: Industry grows despite shift towards community-based treatments Psychiatric Hospitals in Australia This industry consists of hospitals that primarily provide specialist psychiatric ...

  • Industries : Medical Facility, Healthcare
  • Countries : Australia
Healthcare and Pharmaceuticals Report New Zealand 2013

Healthcare and Pharmaceuticals Report New Zealand 2013

  • $ 190
  • Industry report
  • November 2013
  • by The Economist Intelligence Unit

Disease trends;Healthcare;Healthcare;Healthcare;Pharmaceuticals and biotechnology;Healthcare;Spending and provision NCAIS: 62 SIC: 80

  • Industries : Healthcare
  • Countries : New Zealand
Emerging NIPT Market in Asia Pacific

Emerging NIPT Market in Asia Pacific

  • $ 1 200
  • Industry report
  • November 2013
  • by RNCOS

Non-Invasive Prenatal Testing (NIPT) has catapulted the growth in the molecular diagnostics market. In the US, where the test was initially launched, the market is expected to grow at a CAGR of 49% during ...

  • Industries : Genomics
  • Countries : Asia, China, Japan, Australia
Healthcare and Pharmaceuticals Report Australia August 2013

Healthcare and Pharmaceuticals Report Australia August 2013

  • $ 190
  • Industry report
  • August 2013
  • by The Economist Intelligence Unit

Disease trends;Healthcare;Healthcare;Healthcare;Pharmaceuticals and biotechnology;Healthcare;Spending and provision NCAIS: 62 SIC: 80

  • Industries : Healthcare
  • Countries : Australia

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.